DCAT Value Chain Insights’ Production to Prescription
DCAT
53 episodes
3 weeks ago
Without question, evolving US tariff and trade policy was the story of the year, and how such policy will be implemented looms large. At the same time, the normal course of business in the bio/pharmaceutical industry—new drug approvals and the progression of pipelines, including new modalities—was also top of mind. In this special episode of the Production to Prescription podcast, 2025: The Bio/Pharma Industry’s Year in Review, we provide key insights from industry experts and a snapshot of k...
All content for DCAT Value Chain Insights’ Production to Prescription is the property of DCAT and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Without question, evolving US tariff and trade policy was the story of the year, and how such policy will be implemented looms large. At the same time, the normal course of business in the bio/pharmaceutical industry—new drug approvals and the progression of pipelines, including new modalities—was also top of mind. In this special episode of the Production to Prescription podcast, 2025: The Bio/Pharma Industry’s Year in Review, we provide key insights from industry experts and a snapshot of k...
Global API Outlook: Will Supply Lines Change Amid Tariff Uncertainty?
DCAT Value Chain Insights’ Production to Prescription
16 minutes
8 months ago
Global API Outlook: Will Supply Lines Change Amid Tariff Uncertainty?
As evolving US trade policy looms, what are the demand–supply fundamentals now in the global market for active pharmaceutical ingredients (APIs)? A look at the demand side—size, growth rates, and trends— and the supply side—key segments for global API manufacturing and its geographic dispersion. Plus, examining the impact of potential tariffs on manufacturing and supply chains. Support the show
DCAT Value Chain Insights’ Production to Prescription
Without question, evolving US tariff and trade policy was the story of the year, and how such policy will be implemented looms large. At the same time, the normal course of business in the bio/pharmaceutical industry—new drug approvals and the progression of pipelines, including new modalities—was also top of mind. In this special episode of the Production to Prescription podcast, 2025: The Bio/Pharma Industry’s Year in Review, we provide key insights from industry experts and a snapshot of k...
